Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.11.22.389056: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study overview and subjects: The study was approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol, HUGTiP (reference PI-20-122 and PI-20-217) and all participants provided written informed consent before inclusion.
Consent: Study overview and subjects: The study was approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol, HUGTiP (reference PI-20-122 and PI-20-217) and all participants provided written informed consent before inclusion.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not … SciScore for 10.1101/2020.11.22.389056: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study overview and subjects: The study was approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol, HUGTiP (reference PI-20-122 and PI-20-217) and all participants provided written informed consent before inclusion.
Consent: Study overview and subjects: The study was approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol, HUGTiP (reference PI-20-122 and PI-20-217) and all participants provided written informed consent before inclusion.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, Nunc MaxiSorp ELISA plates were coated with 50 μL of capture antibody (anti-6x-His antibody clone HIS.H8; 2 μg/mL; Thermo Fisher Scientific, Waltham, MA, USA) in phosphate-buffered saline (PBS) overnight at 4°C. anti-6x-Hissuggested: NoneThe HRP conjugated (Fab)2 goat anti-human IgG (Fc specific) (1/20,000) (Jackson ImmunoResearch, Ely, UK) was used as a secondary antibody and incubated for 30 minutes at room temperature. anti-human IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Supernatants were harvested 48 hours after transfection, filtered at 0.45 μm, frozen, and titrated on HEK293T cells overexpressing WT human ACE-2 (Integral Molecular, Philadelphia, PA, USA). HEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)Then, 2×104 HEK293T/hACE2 cells (Integral Molecular) treated with DEAE-Dextran (Sigma-Aldrich) were added. HEK293T/hACE2suggested: NoneSoftware and Algorithms Sentences Resources The KING cohort included more than 200 individuals with a documented positive RT-qPCR result from nasopharyngeal swab and/or a positive serological ELISA test performed in our hospital, irrespective of age and disease severity―including asymptomatic status. KINGsuggested: (KING, RRID:SCR_009251)The values were normalized, and the ID50 was calculated by plotting the log of plasma dilution vs. response―Variable slope (four parameters) in Prism 8.4.3 (GraphPad Software, San Diego, CA, USA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)All analyses were performed with Prism 8.4.3 (GraphPad Software) and R version 4.0 (R Foundation for Statistical Computing). Prismsuggested: (PRISM, RRID:SCR_005375)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-